home > drugs a-z list > nasacort aq (triamcinolone acetonide) drug center > nasacort aq (triamcinolone acetonide) drug - side effects and drug interactions

Systemic and local corticosteroid use may result in the following:

• Epistaxis, Candida albicans infection, nasal septal perforation, impaired wound healing [see WARNINGS AND PRECAUTIONS]
• Glaucoma and Cataracts [see WARNINGS AND PRECAUTIONS]
• Immunosuppression [see WARNINGS AND PRECAUTIONS]
• Hypothalamic-pituitary-adrenal (HPA) axis effects, including growth reduction [see WARNINGS AND PRECAUTIONS, Use in Specific Populations]

Clinical Trials Experience

In placebo-controlled, double-blind, and open-label clinical studies, 1483 adults and children 12 years and older received treatment with NASACORT AQ (triamcinolone acetonide) Nasal Spray. These patients were treated for an average duration of 51 days. In the controlled trials (2-5 weeks duration) from which the following adverse reaction data are derived, 1394 patients were treated with NASACORT AQ (triamcinolone acetonide) Nasal Spray for an average of 19 days. In a long-term, open-label study, 172 patients received treatment for an average duration of 286 days. Adverse reactions from 12 studies in adults and adolescent patients 12 to 17 years of age receiving NASACORT AQ (triamcinolone acetonide) Nasal Spray 27.5 mcg to 440 mcg once daily are summarized in Table 1.

In clinical trials, nasal septum perforation was reported in one adult patient who received NASACORT AQ (triamcinolone acetonide) Nasal Spray.

Table 1 - Adverse drug reactions > 2% and greater than placebo with NASACORT AQ (triamcinolone acetonide) Nasal Spray 220 mcg treatment in studies in adults and adolescents 12 years and older

A total of 602 children 6 to 12 years of age were studied in 3 double-blind, placebo-controlled clinical trials. Of these, 172 received 110 mcg/day and 207 received 220 mcg/day of NASACORT AQ (triamcinolone acetonide) Nasal Spray for two, six, or twelve weeks. The longest average durations of treatment for patients receiving 110 mcg/day and 220 mcg/day were 76 days and 80 days, respectively. One percent of patients treated with NASACORT AQ (triamcinolone acetonide) were discontinued due to adverse experiences. No patient receiving 110 mcg/day and one patient receiving 220mcg/day discontinued due to a serious adverse event. A similar adverse reaction profile was observed in pediatric patients 6-12 years of age as compared to adolescents and adults with the exception of epistaxis which occurred in less than 2% of the children studied. Adverse reactions from 2 studies in children 4 to 12 years of age receiving NASACORT AQ (triamcinolone acetonide) Nasal Spray 110 mcg once daily are summarized in Table 2.

Table 2 - Adverse drug reactions > 2% and greater than placebo with NASACORT AQ (triamcinolone acetonide) Nasal Spray 110 mcg treatment in US studies in patients 4 to 12 years of age

A total of 474 children 2 to 5 years of age were studied in a 4-week double-blind, placebo-controlled clinical trial. Of these, 236 received 110 mcg/day of NASACORT AQ (triamcinolone acetonide) Nasal Spray for a mean duration of 28 days. No patient discontinued due to a serious adverse event. Adverse reactions from the single placebo-controlled study in children 2 to 5 years of age receiving NASACORT AQ (triamcinolone acetonide) Nasal Spray 110 mcg once daily are summarized in Table 3.

Table 3 - Adverse drug reactions > 2% and greater than placebo with NASACORT AQ (triamcinolone acetonide) Nasal Spray 110 mcg treatment in children 2 to 5 years of age

In the event of accidental overdose, an increased potential for these adverse experiences may be expected, but acute systemic adverse experiences are unlikely. [See OVERDOSAGE]

Post-Marketing Experience

In addition to the adverse drug reactions reported during clinical studies and listed above, the following adverse events have been identified during post-approval use of NASACORT AQ (triamcinolone acetonide) Nasal Spray. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Events that have been reported during post-marketing experience include: nasal discomfort and congestion, sneezing, alterations of taste and smell, nausea, insomnia, dizziness, fatigue, dyspnea, decreased blood cortisol, cataract, glaucoma, increased ocular pressure, pruritus, rash, and hypersensitivity.

No information provided.

Last reviewed on RxList: 10/27/2008
This monograph has been modified to include the generic and brand name in many instances.